Condition
Sickle-Cell Disease With Crisis
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06315920Phase 3Not Yet RecruitingPrimary
Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department
NCT06399107Phase 1Recruiting
Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
NCT05388188UnknownPrimary
DSUVIA in Patients With SCD VOC Present in the ED
Showing all 3 trials